RESEARCH ARTICLE

Prenatal lead exposure is associated with decreased cord blood DNA methylation of the glycoprotein VI gene involved in platelet activation and thrombus formation

Karin Engström, Filip Rydbeck, Maria Kippler, Tomasz K. Wojdacz, Shams Arifeen, Marie Vahter and Karin Broberg

1Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden; 2Unit of Metals and Health, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 3International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR,B), Dhaka, Bangladesh

*Correspondence address. Unit of Metals and Health, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Tel: +46737823750; Fax: +468336981; E-mail: karin.broberg@ki.se

Abstract

Early-life lead exposure impairs neurodevelopment and later exposure affects the cardiovascular system. Lead has been associated with reduced global 5-methylcytosine DNA methylation, suggesting that lead toxicity acts through epigenetic mechanisms. The objective of this study is to clarify how early-life lead exposure alters DNA methylation of specific genes, using an epigenomic approach. We measured lead concentrations in urine [gestational week (GW), 8] and erythrocytes (GW 14), using inductively coupled plasma mass spectrometry, for 127 pregnant mothers recruited in the MINIMat food and supplementation cohort in rural Bangladesh. Cord blood DNA methylation was analyzed with the Infinium HumanMethylation450K BeadChip, and top sites were validated by methylation-sensitive high-resolution melt curve analysis. Maternal urinary lead concentrations (divided into quartiles) showed significant (after adjustment for false discovery rate) inverse associations with methylation at nine CpGs. Three of these sites were in the 5′-end, including the promoter, of glycoprotein IV (GP6); cg18355537 (q = 0.029, β = −0.30), cg25818583 (q = 0.041, β = −0.18), and cg23796967 (q = 0.047, β = −0.17). The methylation in another CpG site in GP6 was close to significant (cg05374025, q = 0.057, β = −0.23). The erythrocyte lead concentrations (divided into quartiles) were also inversely associated with CpG methylation in GP6, although this was not statistically significant after false discovery rate adjustments. Eight CpG sites in GP6 constituted a differentially methylated region in relation to urinary lead (P = 0.005, q = 0.48) and erythrocyte lead (P = 0.007, q = 0.46). In conclusion, we found that moderate prenatal lead exposure appears to epigenetically affect GP6, a key component of platelet aggregation and thrombus formation, suggesting a novel link between early lead exposure and cardiovascular disease later in life.

Key words: cardiovascular disease; DNA methylation; epigenetic regulation; GPVI; Pb; thrombosis; differently methylated region

Received 3 July 2015; revised 15 September 2015; accepted 9 October 2015

© The Author 2015. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Lead, one of the environmental chemicals most toxic to developing children, readily passes the placenta and reaches the fetus [1], and primarily impairs neurodevelopment of the offspring [2-5]. In fact, recent risk assessments showed that lead toxicity appears to have no exposure threshold [4, 6-8]. Although oxidative stress and interaction with essential elements like calcium and zinc are often considered to be the primary mechanisms of lead toxicity [9, 10], recent research has suggested other mechanisms. Interference with regulation of gene expression through alteration of 5-cytosine DNA methylation may have particular importance for lead’s long-lasting effects [11, 12]. The few studies that address epigenetic effects of lead have mainly focused on methylation in retrotransposons (Alu and LINE1 families), which compose a large part of the human genome (25%) and function as a proxy for global methylation. Wright et al. [13] reported an inverse association between methylation of LINE1 and post-partum lead concentrations in the patella of selected women in the sub-cohort of 500 women that had measured lead in urine. Three of these sites are located in the 5’-end of the glycoprotein IV gene (GP6) on chromosome 19: cg18355337 (Fig. 1) (q = 0.029, \( \beta = -0.30 \)), cg25818583 (q = 0.047, \( \beta = -0.17 \)), and cg23796967 (q = 0.041, \( \beta = -0.18 \)). In addition, lead in urine was near-significantly associated with an additional CpG site in GP6 (cg05374025, q = 0.057, \( \beta = -0.23 \)). These four CpG sites in GP6 were located close to each other either in the promoter (cg23796967) or the promoter-flanking region. The CpGs in GP6 were also associated with decreasing methylation with increasing lead in erythrocytes (divided into quartiles), although this had lower magnitude compared with lead in urine and was not statistically significant after adjustment for FDR: cg18355337 (unadjusted \( P = 8 \times 10^{-6} \), q = 0.20, \( \beta = -0.25 \)), cg25818583 (unadjusted \( P = 2 \times 10^{-4} \), q = 0.40, \( \beta = -0.15 \)), cg23796967 (unadjusted \( P = 6 \times 10^{-5} \), q = 0.32, \( \beta = -0.14 \)), and cg05374025 (unadjusted \( P = 2 \times 10^{-4} \), q = 0.41, \( \beta = -0.18 \)).

Other CpGs that were significantly associated with urinary lead were situated in the secretin receptor (SCTR), olfactomedin 2 (OLF2M), complexin 1 (CPLX1), as well as three CpGs in intergenic regions for which the closest transcription start sites belonged to the genes prospero homeobox 1 (PROX1), 8306 basepairs 5’ of the CpG, transmembrane protein 173 (TMEM173), 35 240 basepairs 5’ of the CpG, and potassium channel, voltage-gated modifier subfamily F, member 1 (KCNF1), 52 332 basepairs 3’ of the CpG.

Maternal lead in erythrocytes was significantly (after FDR-adjustments) associated with the methylation status of two CpGs (Table 3): one CpG in fragile histidine triad (FHIT) on chromosome 3 (q = 0.001, \( \beta = -0.10 \)) and one CpG in an intergenic region of chromosome 22, where the closest transcription start site (2898 basepairs 5’ of the CpG) belonged to the gene Shisa family member 8 (SHISAB) (q = 0.002, \( \beta = -0.11 \)).

None of the top genes (Tables 2 and 3) were significantly associated with concentrations of arsenic in urine or cadmium in blood. We observed no differences between boys and girls in

| Variable | Median (5-95th percentiles) or N (%) |
|----------|-------------------------------------|
| Maternal characteristics |  |
| Age (years) | 25 (17-36) |
| BMI (kg/m²; GW8) | 20 (17-29) |
| Betel chewing in pregnancy, yes/no (yes %) | 73/52 (58/42%) |
| Urinary lead concentrations (µg/l; GW8) | 3.1 (1.4-8.6) |
| Quartile 1 | 1.7 (0.9-2.2) |
| Quartile 2 | 2.6 (2.4-3.1) |
| Quartile 3 | 3.7 (3.2-4.6) |
| Quartile 4 | 5.9 (4.6-15) |
| Erythrocyte lead concentrations (µg/kg; GW14) | 94 (42-196) |
| Quartile 1 | 49 (29-68) |
| Quartile 2 | 83 (96-94) |
| Quartile 3 | 113 (96-131) |
| Quartile 4 | 168 (132-279) |
| Urinary arsenic metabolites (µg/l; GW8) | 68 (20-440) |
| Blood cadmium (µg/kg; GW14) | 1.3 (0.6-3.0) |
| Newborn characteristics |  |
| Boys/girls | 62/65 (49/51%) |
| Gestational age at birth (weeks) | 39 (36-42) |
| Birth weight (g) | 2800 (220-3300) |

BMI, body mass index; N, number of individuals, GW, gestational week.

*Number of individuals with data on urinary lead concentrations was 125 and with data on erythrocyte lead concentrations was 117.*

*Adjusted to average specific gravity of 1.012.*

Results

Descriptive data are listed in Table 1. The median body mass index was 20 kg/m² and 30% of the women had body mass index < 18.5 kg/m². We had data on dietary lead concentrations for 125 individuals and data on erythrocyte lead concentrations for 117 individuals. The maternal concentrations of lead varied 20-fold in urine (ranging from 0.81 to 17 µg/dl, adjusted for specific gravity) and 10-fold in erythrocytes (ranging from 26 to 300 µg/kg erythrocytes) and both showed skew distributions. The concentrations of lead in erythrocytes and urine of the studied women did not differ from the concentrations among all women in the sub-cohort of 500 women that had measurements on lead concentrations (P = 0.32 and 0.78, respectively) [16]. The correlation between lead concentrations in erythrocytes and urine was \( r = 0.44 \) (P < 0.001).

Differentially Methylated Positions Associated with Lead

Maternal lead in urine (divided into quartiles) was significantly [after adjustments for false discovery rate (FDR)] associated with the methylation status of nine Cpgs, and for all these Cpgs, increasing lead in urine was associated with decreasing methylation of DNA obtained from cord blood samples at delivery (Table 2). Three of these sites are located in the 5’-end of the glycoprotein IV gene (GP6) on chromosome 19: cg18355337 (Fig. 1) (q = 0.029, \( \beta = -0.30 \)), cg25818583 (q = 0.047, \( \beta = -0.17 \)), and cg23796967 (q = 0.041, \( \beta = -0.18 \)). In addition, lead in urine was near-significantly associated with an additional Cpg site in GP6 (cg05374025, q = 0.057, \( \beta = -0.23 \)). These four Cpg sites in GP6 were located close to each other either in the promoter (cg23796967) or the promoter-flanking region. The Cpgs in GP6 were also associated with decreasing methylation with increasing lead in erythrocytes (divided into quartiles), although this had lower magnitude compared with lead in urine and was not statistically significant after adjustment for FDR: cg18355337 (unadjusted \( P = 8 \times 10^{-6} \), q = 0.20, \( \beta = -0.25 \)), cg25818583 (unadjusted \( P = 2 \times 10^{-4} \), q = 0.40, \( \beta = -0.15 \)), cg23796967 (unadjusted \( P = 6 \times 10^{-5} \), q = 0.32, \( \beta = -0.14 \)), and cg05374025 (unadjusted \( P = 2 \times 10^{-4} \), q = 0.41, \( \beta = -0.18 \)).

The correlation between lead concentrations in erythrocytes and urine was \( r = 0.44 \) (P < 0.001).

Table 1. characteristics of the 127* mother–child pairs included in the study

| Variable | Median (5-95th percentiles) or N (%) |
|----------|-------------------------------------|
| Maternal characteristics |  |
| Age (years) | 25 (17-36) |
| BMI (kg/m²; GW8) | 20 (17-29) |
| Betel chewing in pregnancy, yes/no (yes %) | 73/52 (58/42%) |
| Urinary lead concentrations (µg/l; GW8) | 3.1 (1.4-8.6) |
| Quartile 1 | 1.7 (0.9-2.2) |
| Quartile 2 | 2.6 (2.4-3.1) |
| Quartile 3 | 3.7 (3.2-4.6) |
| Quartile 4 | 5.9 (4.6-15) |
| Erythrocyte lead concentrations (µg/kg; GW14) | 94 (42-196) |
| Quartile 1 | 49 (29-68) |
| Quartile 2 | 83 (96-94) |
| Quartile 3 | 113 (96-131) |
| Quartile 4 | 168 (132-279) |
| Urinary arsenic metabolites (µg/l; GW8) | 68 (20-440) |
| Blood cadmium (µg/kg; GW14) | 1.3 (0.6-3.0) |
| Newborn characteristics |  |
| Boys/girls | 62/65 (49/51%) |
| Gestational age at birth (weeks) | 39 (36-42) |
| Birth weight (g) | 2800 (220-3300) |

BMI, body mass index; N, number of individuals, GW, gestational week.

*Number of individuals with data on urinary lead concentrations was 125 and with data on erythrocyte lead concentrations was 117.*

*Adjusted to average specific gravity of 1.012.*
Table 2. differentially methylated positions in cord blood in relation to quartiles of maternal urinary lead concentrations in early gestation

| CpG          | Chr | Position* | Gene                              | Methylation of lead in urine | Methylation of lead in erythrocytes |
|--------------|-----|-----------|-----------------------------------|-------------------------------|-------------------------------------|
| cg18355337   | 19  | 5554972   | GP6                               | −0.30                        | −0.20                               |
| cg25196158   | 1   | 214152979 | NA (PROX1)                        | −0.14                        | −0.09                               |
| cg16943697   | 2   | 12028076  | SCTR                              | −0.10                        | −0.06                               |
| cg03833077   | 19  | 10024709  | OLFM2                             | −0.32                        | −0.20                               |
| cg12504721   | 5   | 138897583 | NA (TMEM173)                      | −0.10                        | −0.07                               |
| cg23796967   | 19  | 55549590  | GP6                               | −0.18                        | −0.10                               |
| cg00145875   | 2   | 11040394  | (potassium channel, voltage gated modifier subfamily F, member 1) | −0.09                        | −0.06                               |
| cg25818583   | 19  | 55549801  | GP6                               | −0.17                        | −0.10                               |
| cg23173307   | 4   | 786244    | CPLX1                             | −0.14                        | −0.09                               |
| cg09442107   | 10  | 3918567   | (kruppel-like factor 6)           | 0.07                         | 0.08                                |
| cg05374025   | 19  | 55549746  | GP6                               | −0.23                        | −0.15                               |
| cg26668675   | 6   | 3114846   | NA (PSORS1C3)                     | −0.17                        | −0.10                               |
| cg25472897   | 8   | 145560555 | SCRT1                             | −0.10                        | −0.06                               |
| cg00436174   | 2   | 128051630 | ERCC3                             | −0.07                        | −0.04                               |
| cg11790196   | 14  | 89995679  | FOXN3                             | −0.29                        | −0.17                               |

*Chr, chromosome; q, FDR-adjusted P value; CI, confidence interval.
*Position according to the Genome Reference Consortium GRCh37 [17].

The average methylation as Beta value for all individuals (ranging from 0 to 1, where 1 means fully methylated).

Prenatal lead exposure and DNA methylation

Figure 1. concentrations of lead in urine and in erythrocytes (both divided into quartiles) is inversely associated with cord blood methylation (showed as Beta-values) of the CpG site cg18355337 in GP6

Differentially Methylated Regions Associated with Lead

For lead in urine, 1010 candidate differentially methylated regions (DMRs) were found (Table 4), of which 861 were inversely associated with lead in urine (85%). For lead in erythrocytes, 626 candidate DMRs were found (Table 5), of which 468 were inversely associated with lead in urine (74%). However, after performing FDR adjustments, none of the DMRs was statistically significantly associated with lead in urine or erythrocytes. For urinary lead, the top hits were four regions in chromosome 6 and one region in chromosome 19, the latter including eight CpG sites in GP6 (P = 0.005, q = 0.48), including all GP6 top hits in the differentially methylated position analysis (Fig. 2). Some of the DMRs situated on chromosome 6 were in major histocompatibility complex genes, such as ring finger protein 39 (RNF39), psoriasis susceptibility 1 candidate 3 (PSORS1C3), and HLA complex group 4b (HCC4P6). Also for lead in erythrocytes, there was also one DMR of eight CpGs in GP6 (P = 0.007, q = 0.46), and several of the top hits were in major histocompatibility complex genes on chromosome 6, including major histocompatibility complex class I H, class II DQ beta I, and DP beta II (HLA-H, HLA-DQB1, HLA-DPB1), HLA complex group 48 (HCC4P6), and lymphocyte antigen 6 complex, locus GSC (LY6G5C).

Validation of GP6 Methylation in Relation to Lead

The sites in GP6 were validated by methylation-sensitive high-resolution melting analyses (MS-HRM) in a subset of the samples (n = 80, based on DNA availability) that had been analyzed by Illumina 450K. The MS-HRM assay covered three sites in
### Table 3. Differentially methylated positions in cord blood in relation to quartiles of maternal erythrocyte lead concentrations in early gestation

| CpG      | Chr. | Positiona | Gene Gene names                               | Directionb | Ranka | Beta c   | 95% CI lower | 95% CI higher | q   | Beta c   |
|----------|------|-----------|----------------------------------------------|------------|-------|----------|--------------|---------------|-----|----------|
| cg01519017  | 3    | 61227050  | RNF39 ring finger protein 39                 | +          | 4.05  | 0.0004   | 0.40          |
| cg16653408  | 22   | 42313569  | NA* (PSORS1C3) (psoriasis susceptibility 1 candidate 3) | +          | 4.05  | 0.0004   | 0.40          |
| cg03978167  | 6    | 33091357  | HLA-DPB2                                     | +          | 4.05  | 0.0004   | 0.40          |
| cg18466158  | 7    | 55304314  | NA (EGFR) (epidermal growth factor receptor) | +          | 4.05  | 0.0004   | 0.40          |
| cg23352003  | 18   | 24237245  | NA (KCTD1) (potassium channel tetramerization domain containing 1) | +          | 4.05  | 0.0004   | 0.40          |
| cg07313720  | 2    | 209029594 | CRYGA crystallin, gamma A                    | –          | 0.19  | 0.0096   | 0.40          |
| cg04452660  | 7    | 48021232  | FOXK1 forhead box K1                         | –          | 0.19  | 0.0096   | 0.40          |
| cg06006773  | 10   | 134759693 | NA (CAP46) (cilia and flagella associated protein 46) | +          | 0.19  | 0.0096   | 0.40          |
| cg22994018  | 11   | 105464797 | NA (GRIA4) (glutamate receptor, ionotropic, AMPA 4) | –          | 0.19  | 0.90      |
| cg5979157   | 19   | 53902687  | ZNF765 zinc finger protein 765                | +          | 0.19  | 0.90      |
| cg11774346  | 21   | 46797899 | NA (COL18A1) (collagen, type XVIII, alpha 1) | –          | 0.19  | 0.90      |
| cg11681818  | 1    | 7891116  | PER3 period circadian clock 3                | +          | 0.19  | 0.90      |
| cg25192902  | 11   | 121163419 | SCDSL sterol-C5-desaturase                   | –          | 0.19  | 0.90      |
| cg24735750  | 2    | 11727173 | GREB1 growth regulation by estrogen in breast cancer 1 | –          | 0.19  | 0.90      |
| cg05749559  | 8    | 36793457 | KCNU1 potassium channel, subfamily U, member 1 | –          | 0.19  | 0.90      |

Chr, chromosome; q, FDR-adjusted P value; CI, confidence interval.

aPosition according to the Genome Reference Consortium GRCh37 [17].

bDirection of association with urinary lead as a continuous variable, divided into quartiles.

cThe strength of evidence for each DMR is summarized with its area [18].

### Table 4. DMRs in cord blood in relation to quartiles of maternal urinary lead concentrations in early gestation

| Gene      | Gene names                               | Chr. | Starta | Enda   | Directionb | Area c | Nr. Cpgs | P unadj. | q   |
|-----------|------------------------------------------|------|--------|--------|------------|--------|----------|----------|-----|
| RNFL3     | ring finger protein 39                   | 6    | 30038998 | 30039600 | +          | 4.05   | 0.0004   | 0.40     |
| NA* (PSORS1C3) | (psoriasis susceptibility 1 candidate 3) | 6    | 31148332 | 31148748 | –          | 1.98   | 0.003    | 0.48     |
| NFYA      | nuclear transcription factor Y, alpha    | 6    | 41068553 | 41068752 | –          | 1.61   | 0.004    | 0.48     |
| CRISP2    | cysteine-rich secretory protein 2        | 6    | 49681178 | 49681391 | –          | 1.43   | 0.005    | 0.48     |
| GP6       | glycoprotein VI (platelet)               | 19   | 55549414 | 55549842 | –          | 1.22   | 0.005    | 0.48     |
| PIWIL2    | piwi-like RNA-mediated gene silencing 2  | 8    | 22132678 | 22133076 | –          | 1.37   | 0.005    | 0.48     |
| Csof63    | chromosome 5 open reading frame 64       | 5    | 126408756 | 126409372 | –         | 1.34   | 0.005    | 0.48     |
| TYW3      | tRNA-yW synthesizing protein 3           | 1    | 75198211 | 75199117 | –          | 1.29   | 0.006    | 0.48     |
| NA (ZBED9) | zinc finger, BED-type containing 9       | 6    | 28601269 | 28601519 | –          | 1.22   | 0.006    | 0.48     |
| KRTCAP3   | keratinocyte associated protein 3         | 2    | 27665017 | 27665711 | –          | 1.15   | 0.007    | 0.48     |
| PSMA8     | proteasome (prosome, macropain) subunit, alpha type 8 | 18   | 23713407 | 23714084 | –          | 1.10   | 0.008    | 0.48     |
| SLFN12    | schlafen family member 12               | 17   | 33759512 | 33760293 | –          | 1.06   | 0.009    | 0.48     |
| PAX8      | paired box 8                            | 2    | 113992762 | 113992930 | +         | 1.05   | 0.009    | 0.48     |
| PXDN      | peroxidasin-like                        | 8    | 52321814 | 52322171 | –          | 1.04   | 0.009    | 0.48     |
| HOC4P6    | HL A complex group 4B                   | 6    | 29894619 | 29894820 | –          | 1.03   | 0.009    | 0.48     |

Chr, chromosome; q, FDR-adjusted P value.

aPosition of start and end of the DMR according to Genome build 37 [17].

bDirection of association with urinary lead (as a continuous variable, divided into quartiles).

cThe strength of evidence for each DMR is summarized with its area [18].

### Discussion

In this study including rural Bangladeshi women with moderate lead exposure, increasing lead in urine in early gestation was associated with decreasing DNA methylation for a number of CpG sites in cord blood of the newborns. In particular, the gene GP6, which codes for glycoprotein VI (protein name GPVI), was identified as a target for lead exposure, which is a novel finding. Urinary lead was significantly associated with three CpGs in the 5′ region of GP6 and eight CpG sites in GP6 constituting a DMR in relation to lead in urine. One of these CpGs was present within the promoter (cg23796967) [19], and the others were situated in proximity to the promoter. This region also shows signs of active regulation of gene expression as judged by active histone marks (Fig. 2), indicating that lead-related DNA methylation in this region may affect the expression of GP6.

### GP6: cg02462535, cg25818583, and cg20651389, all of which were present in the eight-CpG-long DMR of GP6. The MS-HRM analysis showed a significant, inverse correlation between maternal lead in urine or erythrocytes and the degree of DNA methylation (Spearman correlation, rS = -0.37, P = 0.0008 for lead in urine and rS = -0.22, P = 0.055 for lead in erythrocytes).
GPVI is a transmembrane platelet collagen receptor which functions as a dimer and is an important component of platelet activation [20]. Dimerization and activation of GPVI occur in response to damage in a blood vessel, resulting in recruitment of collagen and thrombocytes, which give rise to a platelet plug. An initial response to damage in a blood vessel, resulting in recruitment of collagen and thrombocytes, which give rise to a platelet plug. When activated by collagen, GPVI can also activate leukocytes [21]. Moreover, GPVI has been linked to cardiovascular diseases. Several studies have reported elevated levels of GPVI protein in whole blood of patients with acute coronary syndrome, acute ischemic stroke, transient ischemic attack, or stroke, compared with patients without ischemic conditions [23-26]. Platelets have no nucleus and derive from megakaryocytes in the bone marrow. We can- not tell whether the lead-related methylation of GP6 found in cord blood in this study also reflects the methylation status of GP6 in megakaryocytes in the bone marrow. However, GP6 expression in cord blood as well as during megakaryocyte differentiation has been shown to be dependent on demethylation of the GP6 promoter, where the demethylation correlated with increased mRNA levels [27]. Several studies have linked fatal and non-fatal cardiovascular events to exposure to lead; e.g. studies based on the NHANES II and III data showed strong associations between lead exposure and cardiovascular disease, cardiovascular insult occurs later in life, for whatever reason, higher levels of GPVI might result in stronger platelet activation and increase the risk of cardiovascular problems. Thus, the epi-genetic effect of lead early in life could substantially contribute to the overall adverse cardiovascular effects of lead poisoning later in life and could contribute to lead-induced hypertensive effects [32], antifibrinolytic effects [33], and the procoagulant activation of erythrocytes [34]. Interestingly, a recent study indicated that maternal postpartum bone lead concentrations were associated with increased blood pressure in their children at 10 years of age [35].

We also identified associations between lead in urine or erythrocytes and CpGs in other genes, in particular in the HLA region on chromosome 6, responsible for regulation of the immune system. However, little is known about the immunotoxicity of lead, especially in the general population. Alterations of immunoglobulin levels (e.g. IgE, IgG, and IgA) in serum or saliva, as well as various effects on leukocyte and lymphocyte subtypes have been seen in lead-exposed workers, although several studies found no associations [36]. Furthermore, an earlier study on Japanese lead refinery workers indicated that lead exposure is associated with increased sensitivity to infections [37]. The potential effect of lead on the immune system is an interesting finding, and the immune response among lead-exposed children should be further characterized. Further, the CpG that showed the strongest association with lead in erythrocytes was situated in the fragile histidine triad gene (FHIT), a tumor suppressor gene located in a common fragile site that can be rearranged due to exposure to carcinogens. FHIT plays an important

### Table 5. DMRs in cord blood in relation to quartiles of maternal erythrocyte lead concentrations in early gestation

| Gene      | Gene names                  | Chr | Starta | Enda | Directionb | Areaq | Nr. CpGs | P unadj. q |
|-----------|-----------------------------|-----|--------|------|------------|-------|----------|------------|
| NA4       | (VTRNA2-1)                  | 5   | 135415693 | 135416613 | –        | 2.87  | 16       | 0.001 0.46 |
| GSTT1     | glutathione-S transferase T1 | 22  | 24384105 | 24384573 | +        | 1.60  | 11       | 0.004 0.46 |
| NA (LY6G5C)| (lymphocyte antigen 6 complex, locus G5C) | 6   | 31650735 | 31651094 | –       | 1.51  | 14       | 0.004 0.46 |
| HCG4P6    | HLA complex group 4B         | 6   | 29894619 | 29894946 | –       | 1.50  | 8        | 0.005 0.46 |
| NFYA      | nuclear transcription factor Y, alpha | 6   | 41068553 | 41068752 | –       | 1.49  | 7        | 0.005 0.46 |
| LSEM1     | leucine-rich single-pass membrane protein 1 | 7   | 112121036 | 112121259 | +      | 1.47  | 2        | 0.005 0.46 |
| HLA-H     | major histocompatibility complex, class I, H | 6   | 29855110 | 29856070 | –       | 1.29  | 9        | 0.006 0.46 |
| NA (ZFP57) | (ZFP57 zinc finger protein) | 6   | 29648525 | 29649084 | +       | 1.25  | 10       | 0.006 0.46 |
| GP6       | glycoprotein VI (platelet)   | 19  | 55549414 | 55549842 | –       | 1.22  | 8        | 0.007 0.46 |
| AURKC     | aurora kinase C              | 19  | 57741988 | 57742444 | –     | 1.11  | 10       | 0.008 0.46 |
| VWA7      | von Willebrand factor A domain containing 7 | 6   | 31744545 | 31745181 | –    | 1.10  | 12       | 0.008 0.46 |
| HLA-DQB1  | major histocompatibility complex, class II, DQ beta 1 | 6   | 32632937 | 32633163 | –    | 1.08  | 8        | 0.009 0.46 |
| HLA-DPB2  | major histocompatibility complex, class II, DP beta 2 | 6   | 33091242 | 33091841 | –    | 0.96  | 8        | 0.011 0.53 |
| DPPA5     | developmental pluripotency associated 5 | 6    | 74063982 | 74064594 | –    | 0.91  | 7        | 0.012 0.56 |
| NA (RPTN) | (repetin)                    | 1   | 152161237 | 152162025 | –    | 0.86  | 7        | 0.014 0.57 |

Chr, chromosome; q, FDR-adjusted P value.

aPosition of start and end of the DMR according to Genome build 37 [17].

bDirection of association with erythrocyte lead (as a continuous variable, divided into quartiles).

The strength of evidence for each DMR is summarized with its area [38].

NA, not applicable, i.e. the CpG is not present in any known gene, the gene name in brackets denotes the gene with the closest transcription start site.
role in lung cancer development [38]. However, its role in lead-related carcinogenesis is unknown.

There were a larger number of statistically significant findings for lead measured in urine, measured very early in pregnancy (gestational week, GW, 8), compared with lead measured in erythrocytes, measured somewhat later in pregnancy (GW14). It is not clear if the timing of lead exposure influences the effect of lead on DNA methylation. Lead in urine is considered a short-term marker, whereas lead in erythrocytes reflects approximately the last month of exposure [39]. Also, the erythrocyte lead concentrations might have been influenced by early plasma expansion in pregnancy. Another possibility is that the study included somewhat fewer individuals with data on lead in erythrocytes (N = 117), compared to those with data on lead in urine (N = 125), resulting in lower power for associations with erythrocyte lead.

The median concentration of lead in maternal erythrocytes was 94 μg/kg, corresponding to 4 μg/dl in whole blood, assuming 99% of blood lead in the erythrocytes, 41% hematocrit, and an erythrocyte density factor of 1.06 kg/l. These levels are similar to those observed in pregnant women in China and Mexico [40, 41] and higher than those measured in pregnant women in Canada and Germany [42, 43].

One possible drawback of this study is that we were not able to separate cells from blood samples in the field. Therefore, we measured DNA methylation in mixed mononuclear cells from cord blood, i.e. cells that may have partly different methylation patterns. Thus, there is a possibility that a potential cell-specific effect of lead might blur associations between DNA methylation and prenatal lead exposure. However, we performed surrogate variable analysis to adjust for sources of noise such as variation in DNA methylation from different cell types. Importantly, the general lead-associated decreased methylation of specific genes identified here is in accordance with previous studies in newborns [44] and adults [45, 46]. We also conducted sensitivity analyses, in which we adjusted for environmental factors. However, other environmental factors for which we have no data, such as prenatal stress, may influence methylation status in newborns [47].

In conclusion, lead exposure early in life was associated with decreased DNA methylation of GP6, a key component in platelet activation. Decreased methylation of this gene might be a mechanism for lead-related cardiovascular disease. The functional significance of alterations in gene expression and protein levels due to changes in methylation in GP6 is not known, and further studies are needed to clarify this.

Methods

Study Area and Design

This study was conducted in a non-industrialized, rural area called Matlab, located about 50 km southeast of Dhaka, Bangladesh, where moderate lead exposure (range of blood lead concentrations, calculated from erythrocyte lead concentrations, in early pregnancy was 1.4–11.5 μg/dl) has been documented [16]. Main lead sources were suggested to be food and drinking water, cooking pots, and tin roofs and walls, commonly used in the area. In Matlab, the International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) operates a central hospital and four connected health care facilities, as well as a health and demographic surveillance system, which is updated monthly with information collected by community health research workers.

This study was nested in a large randomized food and micronutrient supplementation trial conducted during pregnancy [Maternal and Infant Nutrition Interventions in Matlab (MINIMat)] [48]. In total, 4436 pregnant women were found to be eligible (viable fetus, gestational age <14 weeks, no severe illness, and consent for participation) and thereafter enrolled in the MINIMat trial from November 2001 to October 2002. The supplementation in the intervention trial consisted of food supplementation (starting in early- or mid-pregnancy) and one of three different micronutrient supplemenations (provided daily from GW 14): (i) 30 mg iron and 400 mg folic acid; (ii) 60 mg iron and 400 mg folic acid; or (iii) a capsule with 15 micronutrients, including 30 mg iron and 400 mg folic acid [49].

For this study, we selected a subset of 127 women who were enrolled in the MINIMat trial from October 2002 to October 2003, gave birth to a singleton child at the health care facilities during early day time, and had cord blood collected at delivery [50]. The main reasons for the low number of women in the present subset are a high frequency of home deliveries (>60 %) and that many deliveries at the health care facilities occurred in late afternoon or night, when the logistics did not allow for processing and transport of samples to the laboratory in Dhaka. When comparing these 127 women with all other women who were enrolled in the MINIMat trial from October 2002 to October 2003, gave birth to a single child (n = 1729), the subset of 127 women had slightly higher socioeconomic status and were more likely to be primiparous [51]. Of the 127 mother–child pairs, 125 had data on maternal lead concentrations in urine, and 117 had data on maternal lead concentrations in erythrocytes. The study was approved by the ethics committees at icddr,b (Dhaka, Bangladesh) and the Karolinska Institutet (Stockholm, Sweden). Consent was obtained from all participants, and participants were free to refrain from any part of the study at any time.

Analysis of Lead

Lead exposure during pregnancy was assessed based on concentrations in maternal urine collected at the time of detection of pregnancy by urine sticks, i.e. at about GW8, and in maternal erythrocytes collected at supplementation baseline, about GW14. Lead concentrations in urine and erythrocytes were measured by inductively coupled plasma mass spectrometry (Agilent 7500ce, Agilent Technologies, Japan), with the collision/reaction cell system operating in standard mode (no gas), at the Karolinska Institutet, Stockholm. The sample preparation method and a detailed description of the inductively coupled plasma mass spectrometry analyses have been previously published [16, 52, 53]. All samples had detectable levels of lead.

Quality control was assessed by analyses of two commercial control materials (Seronorm Trace Elements Urine Blank, REF 201305, LOT OK4636 and Seronorm Trace Elements Urine, REF 201205, LOT NO2525). To compensate for variations in the dilution of urine, concentrations were adjusted to the mean specific gravity for mothers’ urine (1.012) measured using a digital refractometer (EUROMEXRD712 clinical refractometer; EROMEX, Arnhem, Netherlands) [54]. Prenatal exposure to arsenic and cadmium (maternal sum of arsenic metabolite concentrations in urine and maternal cadmium concentrations in blood) were measured in GW8 as described previously [51, 55].

Analysis of DNA Methylation

Umbilical cord blood (mixed arterial and venous blood) was collected at birth in heparin-coated sterile vials (Becton Dickinson,
Statistical Analysis

After filtering, 426433 probes were left for further analyses. Principal component analysis (PCA) was performed to evaluate the influence of technical and biological variables on DNA methylation and thus should be considered as covariates in the models. For the PCA, we employed the universally applicable singular value decomposition. The PCA was first performed on DNA methylation values expressed as raw normalized M values, and it showed that the M values were associated with analysis plate in the first and second principal components (PCs) (Supplementary Fig. S1, upper panel). These PCs explained 20% of the variance. The data were then adjusted for analysis plate via ComBat adjustment [58]. Second, we performed a new PCA on the ComBat-adjusted M values, where most of the variation due to methylation plate was removed (Supplementary Fig. S1, lower panel). There were no other variables identified with a major impact on DNA methylation based on inspections of the plots showing associations with the PCs (Supplementary Fig. S1, lower panel). ComBat-adjusted M values were then used for downstream analyses.

Cord blood contains different types of cells, and cell composition could impact the DNA methylation. The method by Houseman et al. [59], which often is used for estimating cell composition, is based on adult white blood cells as a reference. We instead performed surrogate variable analysis using the “sva” package to remove unwanted variation, such as variation in cell composition, by making surrogate variables that were used in subsequent analyses to adjust for unknown, unmodeled, or latent sources of noise [60]. The sva is closely related to the reference-free EWAS method by Houseman et al. [61].

In the downstream analyses, individuals were grouped into quartiles according to their concentrations of lead in urine or lead in erythrocytes, due to skewed distributions of raw data (also when lead concentrations were natural log transformed) as evident from inspection of histograms. The quartiles for urinary lead and erythrocyte lead, respectively, were used as continuous variables (labelled 1–4). Differentially methylated positions were evaluated by fitting a robust linear regression model to each CpG using the R package limma with adjustment for the surrogate variable obtained from sva. Empirical Bayes smoothing was applied to the standard errors. P values were adjusted for multiple comparisons by the Benjamini-Hochberg FDR method [62] to obtain q-values. A q-value of 0.05 or lower was considered statistically significant. Because we have previously shown that this study population is exposed to arsenic and cadmium [63, 64] and arsenic and cadmium exposure has been associated with DNA methylation [51, 55], we also evaluated whether the top genes were associated with maternal arsenic concentrations in urine (natural log transformed, measured in GW 8) or cadmium concentration in blood (natural log transformed, measured in GW14) (adjusting for surrogate variables obtained). Urine and blood samples were collected prior to food and micronutrient supplementation; the cord blood samples for analysis of DNA methylation were collected at delivery (thus after the supplementation started). We have data on supplementation in a variable called “supplementation group,” including six different groups, which combines data on supplementation of food [two groups: (i) early invitation at GW 9 or (ii) usual invitation at GW20] and micronutrient supplements [two groups with different combinations of iron and folic acid, and one group with iron, folic acid, and 13 additional micronutrients] [48]. We evaluated the data stratified for sex or betel nut chewing (yes/no). Finally, we also conducted sensitivity analyses, where we adjusted for other environmental variables that could potentially influence DNA methylation. Variables included in the analyses were arsenic concentrations in urine (natural log transformed, measured in GW 8), cadmium concentration in blood (natural log transformed, measured in GW14), betel nut chewing (yes/no), as well as supplementation group.
DMRs were evaluated using bumphunter, which also estimated potential unmeasured confounders via sva [18], in the R package minfi. The maximum gap between the CpGs was set to 300 basepairs. The smoothing function was employed and 1000 iterations were performed. All statistical analyses were performed using R (v.3.1.3).

Acknowledgements

This research was supported by the Swedish Research Council for Health, Working Life and Welfare (FORTE); the Swedish Research Council, the Swedish International Development Cooperation Agency; and the Karolinska Institutet. Raw data is available at European Genome-phenome archive (EGA) data repository (https://www.ebi.ac.uk/ega/home) under the study accession ID EGAS00001001575.

Conflict of interest. None declared.

Supplementary Data

Supplementary data are available at EnuEpig online.

References

1. Rollin HB, Rudge CV, Thomassen Y et al. Levels of toxic and essential metals in maternal and umbilical cord blood from selected areas of South Africa—results of a pilot study. J Environ Monit 2009;11:618–27.
2. Bihaqi SW, Bahmani A, Subaiea GM et al. Infantile exposure to lead and late-age cognitive decline: relevance to AD. Alzheimers Dement 2014;10:187–95.
3. Boucher O, Muckle G, Jacobson JL et al. Domain-specific effects of prenatal exposure to PCBs, mercury, and lead on infant cognition: results from the Environmental Contaminants and Child Development Study in Nunavik. Environ Health Perspect 2014;122:310–6.
4. EFSA. Panel on contaminants in the food chain (CONTAM); scientific opinion on lead in food. EFSA J 2010;8:1570.
5. Mendelsohn AL, Dreyer BP, Fierman AH et al. Low-level lead exposure and cognitive development in early childhood. J Dev Behav Pediatr 1999;20:425–31.
6. Lanphear BP, Hormung R, Khoury J et al. Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. Environ Health Perspect 2005;113:894–9.
7. Lucchini RG, Zoni S, Guazzetti S et al. Inverse association of intellectual function with very low blood lead but not with manganese exposure in Italian adolescents. Environ Res 2012;118:65–71.
8. Tellez-Rojo MM, Bellinger DC, Arroyo-Quiroz C et al. Longitudinal associations between lead blood concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Pediatrics 2006;118:e323–30.
9. Flora G, Gupta D, Tiwari A. Toxicity of lead: a review with recent updates. Interdiscip Toxicol 2012;5:47–58.
10. Lidsky TJ, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain 2003;126:5–19.
11. Schneider JS, Kidd SK, Anderson DW. Influence of developmental lead exposure on expression of DNA methyltransferases and methyl cytosine-binding proteins in hippocampus. Toxicol Lett 2013;217:75–81.
12. Zheng G, Tian L, Liang Y et al. delta-Aminolevulinic acid dehydratase genotype predicts toxic effects of lead on workers’ peripheral nervous system. Neurotoxicology 2011;32:374–82.
13. Wright RO, Schwartz J, Wright RJ et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. Environ Health Perspect 2010;118:790–5.
14. Pilsner JR, Hu H, Ettinger A et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. Environ Health Perspect 2009;117:1466–71.
15. Li G, Yang X, Xu M et al. Epigenetic marker (LINE-1 promoter) methylation level was associated with occupational lead exposure. Clin Toxicol (Phila) 2013;51:225–9.
16. Bergkvist C, Kippler M, Hamadani JD et al. Assessment of early-life lead exposure in rural Bangladesh. Environ Res 2010;110:718–24.
17. Rosenbloom KR, Armstrong J, Barber GP et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res 2015;43:D670–81.
18. Jaffe AE, Murakami P, Lee H et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol 2012;41:200–9.
19. Furihata K, Kunicki Tj. Characterization of human glycoprotein VI gene 5’ regulatory and promoter regions. Arterioscler Thromb Vasc Biol 2002;22:1733–9.
20. Clemetson JM, Polgar J, Magnenat F et al. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 1999;274:29019–24.
21. Berndt MC, Metharom P, Andrews RK. Primary haemostasis: newer insights. Haemophilia 2014;20(Suppl 4):15–22.
22. Loyau S, Dumont B, Ollivier V et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol 2012;32:778–85.
23. Bigalke B, Lindemann S, Ehlers R et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27:2165–9.
24. Bigalke B, Geisler T, Stellos K et al. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome. Am Heart J 2008;156:193–200.
25. Bigalke B, Stellos K, Geisler T et al. Glycoprotein VI as a prognostic biomarker for cardiovascular death in patients with symptomatic coronary artery disease. Clin Res Cardiol 2010;99:227–33.
26. Al-Tamimi M, Grigoriasid G, Tran H et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011;117:3912–20.
27. Kanaji S, Kanaji T, Jacquelin B et al. Thrombopoietin initiates megakaryocyte differentiation. Blood 2005;105:3888–92.
28. Lustberg M, Silbergeld E. Blood lead levels and mortality. Circulation 2010;121:65–92.
29. Hara A, Thijs L, Asayama K et al. Blood pressure in relation to lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Environ Res 2009;109:289–98.
30. Menke A, Muntner P, Batuman V et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006;114:1388–94.
31. Navas-Acien A, Guallar E, Silberberg EK et al. Lead exposure and cardiovascular disease—a systematic review. Environ Health Perspect 2007;115:472–82.
32. Nash D, Magder L, Lustberg M et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 2003;289:1523–32.
33. Kaji T, Yamamoto C, Sakamoto M et al. Inhibitory effect of lead on the release of tissue plasminogen activator from human vascular endothelial cells in culture. Toxicology 1992;73:219–27.
34. Shin JH, Lim KM, Noh JY et al. Lead-induced procoagulant activation of erythrocytes through phosphatidylserine exposure may lead to thrombotic diseases. Chem Res Toxicol 2007;20:38–43.
35. Zhang A, Hu H, Sanchez BN et al. Association between prenatal lead exposure and blood pressure in children. Environ Health Perspect 2012;120:445–50.
36. Nordberg G, Fowler B, Nordberg M. Handbook on the Toxicology of Metals, 4th edn. Elsevier, Amsterdam, NL, 2014.
37. Horiguchi S, Endo G, Kiyota I et al. Frequency of cold infections in workers at a lead refinery. Osaka City Med J 1992;38:79–81.
38. Kim JS, Kim H, Shim YM et al. Aberrant methylation of the FHit gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004;25:2165–71.
39. Sakai T. Biomarkers of lead exposure. Ind Health 2000;38:127–42.
40. Liu K, Mao X, Shi J et al. Evaluation of lead and essential elements in whole blood during pregnancy: a cross-sectional study. Ir J Med Sci, in press.
41. Braun JM, Wright RJ, Just AC et al. Relationships between lead biomarkers and diurnal salivary cortisol indices in pregnant women from Mexico City: a cross-sectional study. Environ Health 2014;13:50.
42. Ashley-Martin J, Levy AR, Arbuckle TE et al. Maternal exposure to metals and persistent pollutants and cord blood immune system biomarkers. Environ Health 2015;14:52.
43. Neugebauer J, Wittsiepe J, Kasper-Sonnenberg M et al. The influence of low level pre- and perinatal exposure to PCDD/Fs, PCBs, and lead on attention performance and attention-related behavior among German school-aged children: results from the Duisburg Birth Cohort Study. Ir J Med Sci 2015;218:153–62.
44. Sen A, Cingolani P, Senut MC et al. Lead exposure induces changes in 5-hydroxymethylcytosine clusters in CpG islands in human embryonic stem cells and umbilical cord blood. Epigenetics 2015;10:607–21.
45. Hanna CW, Bloom MS, Robinson WP et al. DNA methylation changes in whole blood is associated with exposure to the environmental contaminants, mercury, lead, cadmium and bisphenol A, in women undergoing ovarian stimulation for IVF. Hum Reprod 2012;27:1401–10.
46. Kovatsi L, Georgiou E, Ioannou A et al. p16 promoter methylation in Pb2+–exposed individuals. Clin Toxicol (Phila) 2010;48:124–8.
47. Rodney NC and Mulligan CJ. A biocultural study of the effects of maternal stress on mother and newborn health in the Democratic Republic of Congo. Am J Phys Anthropol 2014;155:200–9.
48. Persson LA, Arifeen S, Ekstrom EC et al. Effects of prenatal micronutrient and early food supplementation on maternal hemoglobin, birth weight, and infant mortality among children in Bangladesh: the MINIMat randomized trial. JAMA 2012;307:2050–9.
49. UNICEF/WHO/UNU. Composition of a Multi-Micronutrient Supplement to be Used in Pilot Programmes among Pregnant Women in Developing Countries. New York: UNICEF (United Nations Children’s Fund), 1999.
50. Ahmed S, Ahsan KB, Kippler M et al. In utero arsenic exposure is associated with impaired thymic function in newborns possibly via oxidative stress and apoptosis. Toxicol Sci 2012;129:305–14.
51. Kippler M, Engstrom K, Mlakar SJ et al. Sex-specific effects of early life cadmium exposure on DNA methylation and implications for birth weight. Epigenetics 2013;8:494–503.
52. Kippler M, Lonnerdal B, Goessler W et al. Cadmium interacts with the transport of essential micronutrients in the mammary gland—a study in rural Bangladeshi women. Toxicology 2009;257:64–9.
53. Kippler M, Goessler W, Nurmella B et al. Factors influencing intestinal cadmium uptake in pregnant Bangladeshi women—a prospective cohort study. Environ Res 2009;109:914–21.
54. Nurmella B, Lindberg AL, Rahman M et al. Urinary arsenic concentration adjustment factors and malnutrition. Environ Res 2008;106:212–8.
55. Broberg K, Ahmed S, Engstrom K et al. Arsenic exposure in early pregnancy alters genome-wide DNA methylation in cord blood, particularly in boys. J Dev Orig Health Dis 2014;5:288–98.
56. Chen YA, Lemire M, Choufani S et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 2013;8:203–9.
57. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007;35:e41.
58. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118–27.
59. Houseman EA, Accomando WP, Koestler DC et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.
60. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet 2007;3:1724–35.
61. Houseman EA, Molitor J, Marsit CJ. Reference-free cell mixture adjustments in analysis of DNA methylation data. Bioinformatics 2014;30:1431–9.
62. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol 1995;57:289–300.
63. Kippler M, Ekstrom EC, Lonnerdal B et al. Influence of iron and zinc status on cadmium accumulation in Bangladeshi women. Toxicol Appl Pharmacol 2007;222:221–6.
64. Vahter ME, Li L, Nermell B et al. Arsenic exposure in pregnancy: a population-based study in Matlab, Bangladesh. J Health Popul Nutr 2006;24:236–45.